Introduction
The protein binding of drug and membrane permeability were previously investigated for several drugs as major factors for salivary excretion where a Salivary Excretion Classification System was proposed (SECS) [1] .High intestinal permeability corresponds to fraction absorption (Fa) ˃0.9, while high protein binding corresponds to low fraction unbound (fu) of ˂0.1. Based on SECS, class I drugs of high intestinal permeability and low protein binding, such as paracetamol, are subject to salivary excretion. Class II drugs of low permeability and low protein binding, such as metformin, are subject to salivary excretion since low permeability is counterbalanced by low protein binding. Class III drugs of high intestinal permeability and high protein binding, such as rusovastatin, are subject to salivary excretion since high protein binding is counterbalanced by high permeability. Class IV drugs of low intestinal permeability and high protein binding, such as montelukast, are not subject to salivary excretion [1] .
Salivary excretion of some drugs has been reported previously as a good indicator for drug bioavailability, therapeutic drug monitoringdrug abuse and pharmacokinetics. Saliva sampling method is a simple, non-invasive, and cheap with less stress or pain and no risk of infection compared with plasma sampling method [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
Valsartan is a non-peptide angiotensin II type 1 (AT 1 ) receptor blockers [12] .It's rapidly absorbed after oral administration and eliminated mainly as unchanged drug via biliary excretion [13, 14] . In case of renal dysfunction, there is no effect on the pharmacokinetics of valsartan. Also the pharmacokineticsis not affected by age [15] . Valsartan is used for the treatment of hypertension either alone or in combination therapy and its effect in reducing blood pressure persists throughout the 24-h after dosing. It is also effective for heart failure and post myocardial infarction patients [16] . HydrochlorothiSaliva versus Plasma Bioequivalence of Valsartan/ Hydrochlorothiazide in Humans: Validation of Classes II and IV Drugs of the Salivary Excretion Classification System using non-invasive saliva instead of plasma for bioequivalence of valsartan and hydrochlorothiazide (HCT) in humans based on Salivary Excretion Classification System (SECS).
Methods Plasma and resting saliva samples were collected over 24 h after oral administration of single dose 160 mg valsartan and 12.5 mg HCT to 12 healthy male volunteers after 10 h overnight fasting. Plasma and saliva concentrations were determined by validated liquid chromatography-mass spectrometry. WinNonlin program V5.2 was used to determine pharmacokinetic parameters and bioequivalence metrics. Moreover, optimized effective intestinal permeability was estimated using PK-Sim/Mobi program V5.6.
Results and Discussion
Valsartan is SECS class IV drug due of low permeability and high protein binding and hence didn't appear in saliva. However, HCT is SECS class II drug due to low permeability and low protein binding. No significant differences were observed in the pharmacokinetic parameters in both plasma matrix and saliva matrix (P˃0.05). The 90 % confidence intervals did not pass in all parameters due to the high intra-subject variability and small sample size used in this study. Saliva to plasma ratios of HCT were low, yet with high correlation coefficient of 0.96-0.98. So saliva can be used as alternative to plasma sample in pharmacokinetic studies and in bioequivalence when adequate sample size is used.
azide, it's a thiazide diuretic and its well absorbed after oral administration with a bioavailability ranging from 60-80 % [17] . Hydrochlorothiazide is widely used for the treatment of hypertension either alone or in combination with other antihypertensive drugs. Hydrochlorothiazide also usedfor the treatment of edema associated with heart failure, liver cirrhosis and nephrotic syndrome [18] . The combination of valsartan and hydrochlorothiazide provides further blood pressure lowering than the individual components [16] .
Objectives
The aim of this study is to investigate the robustness of using noninvasive saliva sampling method instead of plasma sampling method for this combination (valsartan and hydrochlorothiazide) in bioequivalence and in pharmacokinetic studies for drugs that are excreted in saliva according to SECS.
Methods

Study Design
Saliva pharmacokinetics were compared with plasma pharmacokinetics in 12 healthy male subjects under a fasted state after signing the informed consent and passing the laboratory test to participate in a two-way, cross-over design study with wash-out period of 7 days. Medical history, vital signs, physical examination showed no evidence of clinically significant deviation from normal A single oral dose of valsartan/hydrochlorothiazide 160/12.5 mg of either test drugCo-Diotens ® tablets, batch no. 160159 or reference drug Co-Diovan ® tablets, batch no. T9169 with 240 ml of water was given after 10 h overnight fasting without dietary restriction.Plasma samples and resting (unstimulated) saliva samples were collected at the following times: 0, 0.33, 0.66, 1, 1.33, 1.66, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 post drug administrations during each study period.Blood samples were collected in a heparin tube and separated by centrifuge apparatus. Plasma samples and saliva samples were kept frozen at − 20 °C until analysis.
Assay Methodology
Plasma and saliva samples that kept frozen were assayed by a validated liquid chromatography-mass spectrometry (LC-MS) assay method. The chromatographic conditionsused were, column type: 
Data analysis
Pharmacokinetic parameters
Individual pharmacokinetic parameters for drug concentration of both analytes (valsartan and hydrochlorothiazide) in plasma and saliva were calculated by non-compartmental analysis (NCA), using WinNonlinV5.2. Pharmacokinetic parameters were area under the concentration curves to last collection time (AUC 0→t ) , area under the concentration curves to infinity (AUC 0→∞ ), maximum measured concentration(C max ), time to maximum concentration(T max ), elimination rate constant (K el ) and half-life (t 0 . 5 ). Statistical t-tests were done for pharmacokinetic parameters (AUC 0→24 , AUC 0→∞ , C max ,K el andt 0 . 5 ), while Wilcoxon test was done for T max .
Bioequivalence analysis
Analysis of variance (ANOVA) was done according to EMA guideline on bioequivalence. It includes sequence and subject (sequence) as random effects, treatment and period as fixed effects without interaction terms. Level of significance used was 0.05 for all effects. Also, 90 % confidence intervals and intra-subject variability estimates for primary pharmacokinetic parameters (AUC 0→t , AUC 0→∞ andC max ) for testversusreference after logarithmic transformation were calculated by WinNonlinprogram V5.2.
Dimensional and correlation analysis
Saliva versus plasma concentrations up to median T max were correlated by linear regression using Microsoft Excel program. Dimensional analysis was done on an individual basis for each volunteer. Dimensional analysis offers the advantage of more clear comparisons since ratios are unit less. The following dimensionless ratios were calculated:
However, C * is calculated by using C s /C p at each sampling time for 12 subjects.
Optimized effective intestinal permeability
Effective intestinal permeability (P eff ) values were estimated by PKSim/Mobi program V5.6. This was done by searching for the best parameter values that produce plasma concentration that matches the actual plasma concentration at the same time.
Fraction absorption (Fa) was calculated according to equations below:
Where An is the absorption number, R and t res are radius, set at 1.75 cm, and mean residence time, set at 3 h, in the human small intestine respectively.
Results and Discussion
Valsartan falls into SECS class IV with low permeability (Fa = 0.46) and high protein binding (Fu = 0.05). As a result valsartan didn't appear in saliva. Mean plasma valsartan concentrations of test and reference formulations are shown in ▶Fig. 1. The pharmacokinetic parameters of test and reference formulationswere calculated and showed no significant differences since (P˃0.05), as shown in ▶ table 1.
Bioequivalence metrics and intra-subject variabilityvalues for primary pharmacokinetic parameters,AUC 0→24 , AUC 0→∞ and C max in plasma were calculated. The 90 % confidence intervalsdidn't fall within the acceptance range of 80-125 % because the small sample size used and this is expected due to the high intra-subject variability observed in this study as shown in ▶ table 2. In addition, ANOVAp values showed no significant differences between test and reference in all sources of variability as shown in ▶table 3
Hydrochlorothiazide falls into SECS class II with low permeability (Fa = 0.01) and low protein binding (Fu = 0.33) which is consistent with the previous finding [1] . Mean plasma and saliva hydrochlorothiazide concentrations of test and reference formulationsare shown in ▶ Fig. 2 . The profiles showed good salivary excretionwith correlation coefficient of 0.98 and 0.96 between plasma and saliva up to median T max for test and reference respectively as shown in ▶Fig. 3. The pharmacokinetic parameters of test and reference formulations in both plasma and saliva were calculated and the statistical analysis showed no significant differencesbetween test and reference in both plasma matrix and saliva matrix since (P˃0.05),as shown in ▶tables 4, 5 respectively. Bioequivalence metrics and intra-subject variability values for primary pharmacokinetic parametersAUC 0→24 , AUC 0→∞ and C max in both plasma and saliva were calculated. The 90 % confidence intervals Concentration (µg/ml) fall within the acceptance range of 80-125 %, except for C max that could be due to the small sample size and this is reflected with the high intra-subject variability as shown in ▶table 6. Higher variability in saliva is observed as compared with plasma, which can be due to inter-subject variability in drug protein binding and drug membrane permeability. Hence, more subjects are required in studies using saliva matrix compared with plasma matrix. ANOVA p values showed no significant differences in the pharmacokinetic parameters between test and reference in all sources except Subject (Sequence) in AUC 0→24 and AUC 0→∞ in both plasma and saliva as shown in ▶table 7.
From a regulatory point of view,, bioequivalence studies using saliva matrix is not against international guidelines. For example, the US FDA guidance for industry stated, "The statutory definitions of BA and BE, expressed in terms of rate and extent of absorption of the active ingredient or moiety to the site of action, emphasize the use of pharmacokinetic measures in an accessible biological matrix such as blood, plasma, and/or serum to indicate release of the drug substance from the drug product into the systemic circulation" and "Biological matrix: A discrete material of biological origin that can be sampled and processed in a reproducible manner. Examples are blood, serum, plasma, urine, feces, saliva, sputum, and various discrete tissues." [http://www.fda.gov/cder/guidance/ index.htm]. Also, saliva matrix is mentioned clearly in the Japanese guidance [http://www.nihs.go.jp/drug/BEguide-E.html].
Dimensional analysis for the ratios of saliva to plasma is shown in ▶table 8. It showed low saliva/plasma ratiosin the AUC and C maxwith a longer T max . This could be due to the low permeability of hydrochlorothiazide that led to low saliva to plasma ratios.▶ Fig. 4 shows valsartan observed versus PK-Sim/Mobi predicted plasma concentration with good fitting line between observed and predicted. Optimized effective intestinal permeability estimated was equalto 5.00598 × 10 − 5 cm/s. valsartan has low permeability despite the high partition coefficient (log P) that was correlated with permeability classification according to BCS (Biopharmaceutics Classification System) that classified drugs according to permeability and solubility [19] . It was found that valsartan is exposed to intestinal efflux transporter p-glycoprotein that limits its transport AUC * = saliva AUC 0→24 /plasma AUC 0→24 ; max * = saliva T max /plasma T max ; C max * = salivaC max /plasma C max ; C * = saliva concentration/ plasma concentration = C s /C p; AUC 0→24 area under concentration curves to last collection time, C max maximum measured concentration, T max time to maximum concentration from the intestinal lumen and lead to low intestinal permeability [20, 21] .▶ Fig. 5 shows hydrochlorothiazide observed versus PKSim/Mobi predicted plasma concentration with good fitting line between observed and predicted and the estimated optimized effective intestinal permeability was equal to 7.60281 × 10 − 9 cm/s.
Conclusion
The data collected suggest that salivary hydrochlorothiazide can be used as alternative to plasma sample in pharmacokinetic studiesand in bioequivalence when adequate sample size is used.
